It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Phage display enables to screen probes such as peptide, antibody and nanobody with high
specificity and affinity to the target, providing excellent probes for various analytical or …

Therapeutic antibody development requires selection and engineering of molecules with
high affinity and other drug-like biophysical properties. Co-optimization of multiple antibody …

Molecular evolution is an important step in the development of therapeutic antibodies.
However, the current method of affinity maturation is overly costly and labor-intensive …

Antibody display technologies enable the successful isolation of antigen-specific antibodies
with therapeutic potential. The key feature that facilitates the selection of an antibody with …

Phage therapy, the use of bacteriophages (phages) to treat bacterial infections, is regaining
momentum as a promising weapon against the rising threat of multidrug-resistant (MDR) …

Synthetic antibodies (Abs) represent a category of artificial proteins capable of closely
emulating the functions of natural Abs. Their in vitro production eliminates the need for an …

The search for innovative anti-cancer drugs remains a challenge. Over the past three
decades, antibodies have emerged as an essential asset in successful cancer therapy. The …

Foodborne pathogens are an important cause of food safety problems. However, detection
of low number of pathogens in foods can be challenging, as the available recognition …

In this study, we generated a novel library approach for high throughput de novo
identification of humanized single-domain antibodies following camelid immunization. To …